AcelRx Pharmaceuticals Inc. (ACRX)

2.84
0.07 2.53
NASDAQ : Health Technology
Prev Close 2.77
Open 2.77
Day Low/High 2.70 / 2.86
52 Wk Low/High 1.99 / 5.05
Volume 866.04K
Avg Volume 1.56M
Exchange NASDAQ
Shares Outstanding 78.91M
Market Cap 219.38M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
AcelRx Pharmaceuticals (ACRX) Downgraded From Hold to Sell

AcelRx Pharmaceuticals (ACRX) Downgraded From Hold to Sell

AcelRx Pharmaceuticals (ACRX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CLMS, FCCY, FCS Downgrades: ACRX, MWE, QIHU, RAIL, SBR, TIVO, UCP Initiations: CBMG Read on to get TheStreet Quant Ratings' detailed report:

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on...

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against AcelRx Pharmaceuticals, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 1, 2014

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against AcelRx Pharmaceuticals, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 1, 2014

Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased or otherwise acquired AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals (ACRX) Upgraded From Sell to Hold

AcelRx Pharmaceuticals (ACRX) Upgraded From Sell to Hold

AcelRx Pharmaceuticals (ACRX) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.

AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report

AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report

Shares of AcelRx Pharmaceuticals (ACRX) surged in late morning trading Tuesday after the company reported third-quarter results after the market close Monday that beat analysts' expectations.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACRX, ADT, CMGE, DMRC, FCN, FFBC, GVA, ORBC, PMC, SPOK, TCPC Downgrades: ATVI, BRKR, ICPT, LBIX, LUK, MPAA, PEGA, PHI, RIG Initiations: AAOI, AR, CXP, LDRH, QTS, SFXE, SGM, WNRL, XLRN Read on to get TheStreet Quant Ratings' detailed report:

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on...

AcelRx Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

AcelRx Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action...

INVESTOR ALERT: Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Filed By Glancy Binkow & Goldberg LLP

INVESTOR ALERT: Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Filed By Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP, representing investors of AcelRx Pharmaceuticals, Inc.

Strong On High Volume: AcelRx Pharmaceuticals (ACRX)

Strong On High Volume: AcelRx Pharmaceuticals (ACRX)

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a strong on high relative volume candidate

Why AcelRx Pharmaceuticals (ACRX) Stock Hit a One-Year Low Today

Why AcelRx Pharmaceuticals (ACRX) Stock Hit a One-Year Low Today

Shares of AcelRx Pharmaceuticals (ACRX) plummeted to a 52-week low of $5.27 on Friday after the company announced a delay in resubmitting Zalviso for FDA approval.

The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks

The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks

It's not the hedge fund mogul you expect.

Perilous Reversal Stock: AcelRx Pharmaceuticals (ACRX)

Perilous Reversal Stock: AcelRx Pharmaceuticals (ACRX)

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a "perilous reversal" (up big yesterday but down big today) candidate

4 Biotech Stocks Under $10 to Trade for Breakouts

4 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

Today's Dead Cat Bounce Stock: AcelRx Pharmaceuticals (ACRX)

Today's Dead Cat Bounce Stock: AcelRx Pharmaceuticals (ACRX)

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Why AcelRx Pharmaceuticals (ACRX) Stock Is Plummeting Today

Why AcelRx Pharmaceuticals (ACRX) Stock Is Plummeting Today

AcelRx Pharmaceuticals (ACRX) plummeted Monday after the FDA rejected the company's painkiller dispensing device Zalviso.

FDA Rejects AcelRx Painkiller Dispensing Device (Update)

FDA Rejects AcelRx Painkiller Dispensing Device (Update)

AcelRx believes it can gather all the requested information and re-submit Zalviso to the FDA before the end of the year.

AcelRx Pharmaceuticals (ACRX) Moving On Heavy Volume In The Pre-Market Hours

AcelRx Pharmaceuticals (ACRX) Moving On Heavy Volume In The Pre-Market Hours

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a pre-market mover with heavy volume candidate

4 Biotech Stocks Breaking Out on Big Volume

4 Biotech Stocks Breaking Out on Big Volume

These biotech stocks rising on unusual volume are within range of triggering breakout trades.

Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox

Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events

Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

5 Stocks Spiking on Unusual Volume

5 Stocks Spiking on Unusual Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

First Week of August 16th Options Trading For AcelRx Pharmaceuticals (ACRX)

First Week of August 16th Options Trading For AcelRx Pharmaceuticals (ACRX)

Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACRX options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Oversold Conditions For AcelRx Pharmaceuticals (ACRX)

Oversold Conditions For AcelRx Pharmaceuticals (ACRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AcelRx Pharmaceuticals is Now Oversold (ACRX)

AcelRx Pharmaceuticals is Now Oversold (ACRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of ACRX December 20th Options Trading

First Week of ACRX December 20th Options Trading

Investors in AcelRx Pharmaceuticals Inc saw new options begin trading this week, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Interesting ACRX Put And Call Options For May 17th

Interesting ACRX Put And Call Options For May 17th

Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACRX options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

First Week of ACRX February 2014 Options Trading

First Week of ACRX February 2014 Options Trading

Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the February 2014 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACRX options chain for the new February 2014 contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: D- (Sell)